Edition:
United States

BiondVax Pharmaceuticals Ltd (BVXV.OQ)

BVXV.OQ on NASDAQ Stock Exchange Capital Market

5.31USD
12:39pm EST
Change (% chg)

$0.01 (+0.19%)
Prev Close
$5.30
Open
$5.27
Day's High
$5.31
Day's Low
$5.25
Volume
2,221
Avg. Vol
6,916
52-wk High
$10.75
52-wk Low
$3.04

Latest Key Developments (Source: Significant Developments)

Biondvax Pharmaceuticals Ltd Reports Qtrly Loss Per Share of NIS 0.01 ‍​
Tuesday, 28 Nov 2017 09:00am EST 

Nov 28 (Reuters) - Biondvax Pharmaceuticals Ltd ::BIONDVAX PHARMACEUTICALS LTD - QTRLY LOSS PER SHARE NIS 0.01 ‍​.  Full Article

BiondVax and NIH sign clinical trial agreement for phase 2 trial for universal flu vaccine
Monday, 20 Nov 2017 09:00am EST 

Nov 20 (Reuters) - Biondvax Pharmaceuticals Ltd :BiondVax and NIH sign clinical trial agreement for a phase 2 trial in the U.S. with BiondVax's universal flu vaccine.BiondVax Pharmaceuticals - ‍NIAID is submitting IND to FDA, participant recruitment anticipated to begin after end of 2017/18 flu season​.  Full Article

Ibex Investors reports 5.5 pct passive stake in BiondVax Pharma
Friday, 22 Sep 2017 04:50pm EDT 

Sept 22 (Reuters) - Ibex Investors LLC:Ibex Investors LLC reports 5.5 percent passive stake in BiondVax Pharmaceuticals Ltd as of Sept 14, 2017 - SEC filing.  Full Article

BiondVax announces public offering of American Depositary Shares
Wednesday, 13 Sep 2017 04:56pm EDT 

Sept 13 (Reuters) - BiondVax Pharmaceuticals Ltd :BiondVax announces public offering of American Depositary Shares.BiondVax Pharmaceuticals Ltd - ‍intends to offer for sale ADS each representing 40 of its ordinary shares which are listed on Tel Aviv stock exchange​.  Full Article

Dual-listed BiondVax to voluntarily delist from Tel Aviv Stock Exchange
Thursday, 31 Aug 2017 07:30am EDT 

Aug 31 (Reuters) - BiondVax Pharmaceuticals Ltd :Dual-listed BiondVax to voluntarily delist from Tel Aviv Stock Exchange.BiondVax Pharmaceuticals Ltd - ‍Board has decided to voluntarily delist from Tel Aviv Stock Exchange while maintaining a continued listing on Nasdaq​.BiondVax Pharmaceuticals Ltd - Has formed a committee to identify a new chair of board.BiondVax Pharmaceuticals Ltd - ‍Avner Rotman will continue to serve as chairman until a suitable replacement is identified​.‍Delisting process of BiondVax's shares from trading on TASE will take place by end of 2017​.  Full Article

Biondvax Pharmaceuticals: trial meets both primary endpoints
Thursday, 20 Jul 2017 06:30am EDT 

July 20 (Reuters) - Biondvax Pharmaceuticals Ltd :Biondvax reports positive Phase 2b clinical trial results for its universal flu vaccine.Biondvax Pharmaceuticals Ltd says trial meets both primary endpoints.Biondvax Pharmaceuticals Ltd- ‍statistically significant positive results from Phase 2b clinical trial of M-001​.Biondvax Pharmaceuticals - in one of four H5N1 strains tested, a statistically significant HAI elevation was observed in participants who had received M-001.Biondvax Pharmaceuticals Ltd- ‍confirms that M-001 has a good safety profile and is well-tolerated​.Biondvax-Considering taking opportunity to proceed directly to testing clinical efficacy of vaccination with M-001 alone in pivotal Phase 3 clinical trial​.  Full Article

BiondVax signs lease agreement for facility to manufacture flu vaccine
Tuesday, 18 Jul 2017 07:30am EDT 

July 18 (Reuters) - BiondVax Pharmaceuticals Ltd ::BiondVax signs lease agreement for mid-size commercial facility to manufacture universal flu vaccine.BiondVax Pharma- mid-sized facility is planned to have capacity to annually produce tens of millions of doses of m-001 either in single-dose syringe or in bulk.BiondVax Pharma- facility is planned to have capacity to annually produce tens of millions of doses of M-001 either in single-dose syringe or in bulk.BiondVax Pharmaceuticals Ltd - while construction of facility will begin soon, agreement calls for BiondVax to begin lease payments in October 2018.BiondVax Pharmaceuticals Ltd - length of lease is 10 years with an option for an additional 5 years at BiondVax's discretion.  Full Article

Biondvax Pharmaceuticals and European Investment Bank enter into EUR 20 mln loan agreement
Monday, 19 Jun 2017 07:00am EDT 

June 19 (Reuters) - Biondvax Pharmaceuticals Ltd :Biondvax Pharmaceuticals Ltd - European Investment Bank, co entered into a EUR 20 million loan agreement.  Full Article

Biondvax reports Q2 loss per share NIS 0.02
Thursday, 18 Aug 2016 04:07pm EDT 

Biondvax Pharmaceuticals Ltd : Announces second quarter 2016 financial results and update .Qtrly loss per share NIS 0.02.  Full Article

BRIEF-Biondvax Pharmaceuticals Ltd Reports Qtrly Loss Per Share of NIS 0.01 ‍​

* BIONDVAX PHARMACEUTICALS LTD - QTRLY LOSS PER SHARE NIS 0.01 ‍​ Source text for Eikon: Further company coverage: